Sanofi ADS (SNY US)
SNY US$42.25
20 minute delayed
14 days free access
Join Market Matters and get full access to all our Opinion + Action
Performance
Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.
Share price activity
Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
- Last (Price)
- 42.25
- Change
- ▲ 0.36 (0.85)
- Bid / Ask
- 42.23 - 42.24
- Volume
- 1,028,841
- Turnover
- 30,248,894
- Open
- 41.83
- Day Range
- 41.63 - 42.27
- VWAP
- 42.08
- Prev Close
- 41.89
- Last Trade
- 28/10 4:00pm
Key information
Displays key information on the security, sourced from Morningstar.
- Sector
- Healthcare
- Shares Issued
- 2,415,546,786
- NTA/Share
- 1.72
- Last Dividend
- 2.42
- Dividend Ex Date
- 4 MAY 2026
- Dividend Pay Date
- 3 JUN 2026
Current (EUR) · FY2025
Displays key financial data for the most recent fiscal year, in millions. Note - Per share data is in local currency terms irrespective of reporting currency, and may be different to the stated currency, sourced from Morningstar.
- Revenue
- 46,716.00
- EBITDA
- 12,148.00
- Profit
- 7,813.00
- Earnings Per Share (EPS)
- 3.19
- Dividend Per Share (DPS)
- 2.06
- Yield %
- 5.90
- Market Cap
- 101,224.82
- Price to Earnings Ratio (P/E)
- 23.44
Estimates (EUR) · FY2027
Displays consensus analyst’s estimates for key measures for the next fiscal year, sourced from Morningstar.
- Revenue
- 52,108.57
- EBITDA
- 10,062.54
- Profit
- 9,899.31
- Earnings Per Share (EPS)
- 4.28
- Dividend Per Share (DPS)
- 2.27
Quantitative rating
Displays Morningstar’s Quantitative Equity Research Rating for the security: a star rating from 1 (overvalued) to 5 (undervalued) from the share price against a fair value estimated by a statistical model of Morningstar’s analyst ratings, with the model’s economic moat, financial health and fair value uncertainty, sourced from Morningstar.
Undervalued
- Economic Moat
- Narrow
- Financial Health
- Strong
- Uncertainty
- Medium
Morningstar Quantitative Rating as of 21 OCT 2026.
Quantitative Equity Rating Methodology – view here
Fair value estimate
Displays Morningstar’s quantitative fair value estimate for the security against the current share price, with the band around it: the five-star price below which the model would rate the stock five stars and the one-star price above which it would rate it one star, sourced from Morningstar.
Five-star price 47.59 Fair value 52.74 One-star price 58.45
Morningstar Quantitative Rating as of 21 OCT 2026.
Quantitative valuation
Displays where the share price sits in Morningstar’s quantitative fair value band, from the five-star price (undervalued) to the one-star price (overvalued), with the fair value estimate, the price to fair value ratio, the model’s valuation label and its uncertainty rating, sourced from Morningstar.
Buy
Sell
- Fair Value
- 52.74
- Price / Fair Value
- 0.78
- Valuation
- Undervalued
- Uncertainty
- Medium
Morningstar Quantitative Rating as of 21 OCT 2026. The slider runs from the five-star price (47.59) to the one-star price (58.45).
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
| Ratios |
|---|
| Currency (Price/reporting): USD/EUR |
| Exchange Rate: 1.1133 |
Price, volume and trading statistics for the security, sourced from Morningstar.
| Price - closing or last bid | 40.97 |
| Price - 12 month high | 52.68 |
| Price - 12 month low | 39.07 |
| Pricing date | 20 OCT 2026 |
| Volume - avg. trading volume for the last ten days | 3.64 |
| Market capitalization | 98,169.75 |
| 12 Month High price date | 13 NOV 2025 |
| 12 Month Low price date | 13 OCT 2026 |
| Volume - avg. trading volume for the last 3 months | 3.03 |
| Price - 1 Day % Change | -1.04% |
| Price - 13 week price percent change | -6.35% |
| Price - 26 week price percent change | -13.07% |
| Price - 5 Day % Change | 3.02% |
| Price - 52 week price percent change | -17.50% |
| Price - YTD price percent change | -15.94% |
| Price % Change Month To Date | -3.60% |
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
| EPS excluding extraordinary items - most recent fiscal year | 2.015 |
| EPS excluding extraordinary items - trailing 12 month | 1.626 |
| EPS Normalized - most recent fiscal year | 3.898 |
| Revenue/share - most recent fiscal year | 19.058 |
| Revenue/share - trailing 12 month | 20.164 |
| Book value per share - most recent fiscal year | 27.245 |
| Book value per share - most recent quarter | 26.480 |
| Book value (tangible) per share - most recent fiscal year | 1.718 |
| Book value (tangible) per share - most recent quarter | 0.523 |
| Cash per share - most recent fiscal year | 3.170 |
| Cash per share - most recent quarter | 2.650 |
| Cash Flow per share - most recent fiscal year | 3.576 |
| Cash Flow per share - trailing 12 month | 4.879 |
| Dividend per share - most recent fiscal year | 2.060 |
| Dividends per share - trailing 12 month | 2.419 |
| EBITD per share - trailing 12 month | 3.283 |
| EPS Basic excluding extraordinary items - most recent fiscal year | 2.025 |
| EPS Basic excluding extraordinary items - trailing 12 month | 1.630 |
| EPS including extraordinary items - most recent fiscal year | 3.200 |
| EPS including extraordinary items - trailing 12 month | 1.635 |
| Free Cash Flow per share - trailing 12 month | 4.879 |
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
| P/E excluding extraordinary items, most recent fiscal year | 21.60 |
| P/E Normalized, most recent fiscal year | 8.38 |
| Price to sales - most recent fiscal year | 1.74 |
| Price to Tangible Book - most fiscal year | — |
| Price to Free Cash Flow per Share - most recent fiscal year | 7.20 |
| Price to Cash Flow per share - trailing 12 month | 7.20 |
| Price to Book - most recent fiscal year | 1.35 |
| P/E excluding extraordinary items high, trailing 12 months | 24.26 |
| P/E excluding extraordinary items low, trailing 12 months | 16.49 |
| Net Debt, LFI | 17,226.00 |
| Net Debt, LFY | 11,862.00 |
| Dividend Yield - 5 Year Average | 4.03% |
| Dividend Yield - indicated annual dividend divided by closing price | 5.84% |
| Current Dividend Yield - Common Stock Primary Issue, LTM | 5.90% |
Cash flow, liquidity and leverage measures, sourced from Morningstar.
| Free Cash Flow - most recent fiscal year | 5,228.00 |
| LT debt/equity - most recent fiscal year | 21.91% |
| Payout ratio - most recent fiscal year | 64.68% |
| Total debt/total equity - most recent fiscal year | 28.35% |
| LT debt/equity - most recent quarter | 23.46% |
| Total debt/total equity - most recent quarter | 33.89% |
| Free Cash Flow - trailing 12 month | 11,837.00 |
| Payout ratio - trailing 12 month | 126.09% |
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
| Revenue - most recent fiscal year | 46,716.00 |
| Revenue - trailing 12 month | 48,919.00 |
| EBITD - most recent fiscal year | 12,148.00 |
| EBITD - trailing 12 month | 7,965.00 |
| Earnings before taxes - most recent fiscal year | 6,175.00 |
| Earnings before taxes - trailing 12 month | 5,433.00 |
| Net Income available to common - most recent fiscal year | 7,813.00 |
| Net Income available to common - trailing 12 months | 3,958.00 |
| Earnings before taxes Normalized - most recent fiscal year | 9,437.00 |
| Net Income Available to Common, Normalized - most recent fiscal year | 9,555.00 |
| Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM | 4.19 |
Profitability margins for the most recent fiscal year, sourced from Morningstar.
| Net Profit Margin % - 1st historical fiscal year | 10.65% |
| Net Profit Margin % - trailing 12 month | 8.16% |
| Operating margin - 1st historical fiscal year | 20.54% |
| Operating margin - trailing 12 month | 20.58% |
| Pretax margin - trailing 12 month | 11.11% |
| Pretax margin - 1st historical fiscal year | 13.22% |
| Operating Margin - 5 year average | 22.37% |
| Pretax Margin - 5 year average | 17.55% |
| Free Operating Cash Flow/Revenue, 5 Year Average | 16.98% |
| Free Operating Cash Flow/Revenue, TTM | 24.20% |
| Net Profit Margin - 5 year average | 14.28% |
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
| Return on average assets - most recent fiscal year | 3.85% |
| Return on average assets - trailing 12 month | 3.13% |
| Return on average equity - most recent fiscal year | 7.11% |
| Return on average equity - trailing 12 month | 5.87% |
| Return on average assets - 5 year average | 4.54% |
| Return on average equity - 5 year average | 8.38% |
| Net Income/employee - most recent fiscal year | 66,496.54 |
| Revenue/employee - most recent fiscal year | 624,161.61 |
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
| Revenue growth rate, 5 year | 4.57% |
| EPS growth rate, 5 year | -8.18% |
| Growth rate% - dividend, 3 year | 9.79% |
| Revenue/share (5 yr growth) | 5.15% |
| Growth rate% - Revenue, 3 year | 4.82% |
| Growth rate% - EPS, 3 year | -1.47% |
| Book value per share growth rate, 5 year | 1.18% |
| Capital Spending growth rate, 5 year | 11.18% |
| Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR | -6.99% |
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.
Financial forecast (EUR, millions except per share)
| Actuals | Estimates | |||||||
| 2025 | 2026 | 2027 | 2028 | 2029 | ||||
| Estimate breakdown | ||||||||
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.
Financials (EUR, millions)
| Period end: | DEC 21 | DEC 22 | DEC 23 | DEC 24 | DEC 25 |
| Fiscal year: | 2021 | 2022 | 2023 | 2024 | 2025 |
| Period length: | 12 months | 12 months | 12 months | 12 months | 12 months |
Displays all company announcements released by the company to the exchange, sourced from Morningstar.
Announcements
Announcements are available for ASX-listed companies only.
Opinion
No opinions for this company yet.
Action
No actions for this company yet.
Business Summary
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Relevant suggested news and content from the site
Video
WATCH
Webinar Recording: Are commodities entering a Supercycle?
Recorded Wednesday 24th June @ 12.30pm
Podcast
LISTEN
Thursday 11th September – Dow off -220pts, SPI off -20pts
Daily Podcast Direct from the Desk
Video
WATCH
Buy Hold Sell: The 6 income stocks readers love, plus 2 expert ideas
Recorded 10th June 2026
Podcast
LISTEN
Wednesday 10th September – Dow up +196pts, SPI down -4pts
Daily Podcast Direct from the Desk
